Key Inclusion Criteria:

          -  Participants with histologically confirmed urothelial cancer (UC).

          -  Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1.

          -  Cohort 1: Have had progression or recurrence of urothelial cancer following receipt of
             platinum-containing regimen (cisplatin or carboplatin):

               -  Received a first-line platinum-containing regimen in the metastatic setting or
                  for inoperable locally advanced disease;

               -  Or received neo/adjuvant platinum-containing therapy for localized
                  muscle-invasive urothelial cancer, with recurrence/progression ≤12 months
                  following completion of therapy.

          -  Cohort 1: In addition to above criterion, have had progression or recurrence of
             urothelial cancer following receipt of an Anti-programmed Cell Death Protein 1
             (anti-PD-1)/ Anti-programmed Death Ligand 1 (PD-L1) therapy.

          -  Cohort 2: Were ineligible for platinum-based therapy for first line metastatic disease
             and have had progression or recurrence of urothelial cancer after a first-line therapy
             for metastatic disease with anti-PD-1/PD-L1 therapy. Individual may not have received
             any platinum for treatment of recurrent, metastatic or advanced disease.

          -  Cohort 3: Progression or recurrence of UC following a platinum containing regimen in
             the metastatic setting, or progression or recurrence of UC within 12 months of
             completion of platinum-based therapy as neoadjuvant or adjuvant therapy.

          -  Cohorts 4 and 5: Individual has not received any platinum-based chemotherapy in the
             metastatic or unresectable locally advanced setting. Creatinine clearance of at least
             50 mL/min calculated by Cockcroft-Gault formula or another validated tool. For
             individuals receiving cisplatin at 70 mg/m^2 on Day 1 of every 21-day cycle, a
             creatinine clearance of least 60 mL/min calculated by Cockcroft -Gault formula or
             another validated tool is required. Individuals with creatinine clearance between 50
             to 59 mL/min are to receive a split dose of cisplatin (35 mg/m^2 Day 1 and Day 8 of
             every 21-day cycle).

          -  Adequate renal and hepatic function.

          -  Adequate hematologic parameters without transfusional support.

          -  Individuals must have a 3-month life expectancy.

          -  Have measurable disease by Computed Tomography Imaging (CT) or Magnetic Resonance
             Imaging (MRI) as per RECIST 1.1 criteria.

        Key Exclusion Criteria:

          -  Females who are pregnant or lactating.

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier.

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

          -  Requires concomitant medication interfering with ABCA1 transporter or UGT1A1

          -  Has an active second malignancy.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has known active Hepatitis B or Hepatitis C

          -  Has other concurrent medical or psychiatric conditions

          -  Cohorts 3 to 5: Has active autoimmune disease requiring systemic treatment with
             steroids or other immunosuppressive agent or any condition that in the Investigator's
             judgment precludes treatment with pembrolizumab, has received a live vaccine within 30
             days prior to the first dose of study drug(s), has history or evidence of interstitial
             lung disease (ILD) or non-infectious pneumonitis, has received anti-PD-1/PD-L1 therapy
             previously

          -  Cohorts 4 and 5: Refractory to platinum (i.e., relapsed ≤ 12 months after completion
             of chemotherapy) in the neoadjuvant/adjuvant setting.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.